Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies.
about
The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejectionThe binding sites of monoclonal antibodies to the nonreducing end ofFrancisella tularensis O-antigen accommodate mainly the terminal saccharideAntibody Subclass Repertoire and Graft Outcome Following Solid Organ TransplantationUnderstanding the relationship between biotherapeutic protein stability and solid-liquid interfacial shear in constant region mutants of IgG1 and IgG4Investigating Structure and Dynamics of Proteins in Amorphous Phases Using Neutron Scattering.IgG subclass and heavy chain domains contribute to binding and protection by mAbs to the poly γ-D-glutamic acid capsular antigen of Bacillus anthracis.Nanosecond fluorescence microscopy. Emission kinetics of fura-2 in single cells.Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: potential applications for cellular targeting.Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functionsCharacterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsuleBivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule.Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1.Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection.Functional activities and immunoglobulin variable regions of human and murine monoclonal antibodies specific for the P1.7 PorA protein loop of Neisseria meningitidisProfile of jeffery L. DanglThe structure of dual-variable-domain immunoglobulin molecules alone and bound to antigenExpression of 12 rabbit IgA C alpha genes as chimeric rabbit-mouse IgA antibodies.IgG subclasses and allotypes: from structure to effector functions.Nodular glomerulosclerosis with anti-glomerular basement membrane-like glomerulonephritis; a distinct pattern of kidney injury observed in smokers.B1b cells recognize protective antigens after natural infection and vaccination.Transferrin-antibody fusion proteins are effective in brain targetingIgG4 breaking the rules.Three-dimensional structure of the human myeloma IgG2.Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope proteinDecreased dengue replication and an increased anti-viral humoral response with the use of combined Toll-like receptor 3 and 7/8 agonists in macaquesHematopoietic properties of granulocyte colony-stimulating factor/immunoglobulin (G-CSF/IgG-Fc) fusion proteins in normal and neutropenic rodents.IgG1 protects against renal disease in a mouse model of cryoglobulinaemiaThe solution structures of two human IgG1 antibodies show conformational stability and accommodate their C1q and FcγR ligands.Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3).CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIV-uninfected rhesus macaquesOne disulfide bond in front of the second heavy chain constant region is necessary and sufficient for effector functions of human IgG3 without a genetic hinge.A human anti-Pseudomonas aeruginosa serotype O6ad immunoglobulin G1 expressed in transgenic tobacco is capable of recruiting immune system effector function in vitro.Solution conformation of wild-type and mutant IgG3 and IgG4 immunoglobulins using crystallohydrodynamics: possible implications for complement activation.Generation and characterization of hybridoma antibodies for immunotherapy of tularemia.Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia.Glycosylation of a VH residue of a monoclonal antibody against alpha (1----6) dextran increases its affinity for antigen.The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain.Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation.Continual low-level activation of the classical complement pathway.
P2860
Q26862195-060798CC-CA72-4D9B-991B-FDEE1AB58970Q27679050-9A702A5D-8AFD-4356-B3F8-E1E654C079F4Q28076193-383DFF65-59A1-4BB3-BAB2-CFC7E5B67376Q30357075-3A78CE01-3EDC-4AF0-A538-027021CBF6BDQ30398032-0970616F-E0B8-4A23-8A3E-9C74B36AC9C8Q31116360-B9150CFA-EDA3-45E1-B178-111F3E522582Q33531045-02809DD8-9944-4896-A773-FA58CD66742DQ33685694-FB5BDC2A-4995-4101-8E04-A05D6CFFEA39Q33733443-C00BB3A2-9EA0-4231-8787-1BC1776FBD3FQ33752366-896052EB-C7DE-4403-BFE2-6F35F0DD2B75Q33752377-A5F7A14B-0C4E-4946-9E43-C270F481BFD6Q33754371-1CA2D11F-4C26-4FCD-AD1C-A57922472123Q33843554-9B91969A-2419-41B6-BE81-C66614230E6FQ33974253-F7E6C288-4BE0-4DD7-994D-1E6A8F570C50Q34003805-0125FA80-D91D-406B-88E3-EB1E9A8DB3F7Q34068113-0F18F4C4-8E98-441E-BDB3-2F315927FB3DQ34212743-BDDAC42D-50DF-48E5-9EA7-67EE937B969CQ34308543-D7E45575-E059-46F7-9B3B-AB22E4A4D0DBQ34368678-A389C017-E58A-48CA-BE58-CC4E2830E0DDQ34400641-DF140743-9D04-4DAB-B7B9-D3017DF24800Q34433081-8721162C-C3FE-4142-92F6-7A7CA720B093Q34506062-353E9C6A-EDD9-4299-A19B-A7522EFE68B8Q34534472-8246E287-70A6-41EA-9328-8F261D22DEA1Q34769388-9947B645-87B7-4E9B-8D75-11CFDE700739Q34787140-1E6827E9-F885-4287-A19D-81CE46C27A6DQ34889330-56694186-E441-40FC-B9DE-214B0FFE23ADQ35122746-3283CE2C-5831-4CFB-810B-EFFA4F299BBAQ35127662-5E14837D-7EFC-47F7-9CE9-62F07EE4502EQ35221593-6D483322-69AC-44B2-9D45-1EF2E73745E1Q35583369-6D53D1EA-023A-427A-AE3F-1A3AEE6D68D7Q35693333-253A1B20-4754-46D7-9D9D-FC057013D4D5Q35774772-31AAB950-A0EF-4856-BB64-D4916B88C2A5Q36094806-88333BCE-D04F-4B35-A6D8-00DC3952B7E8Q36156532-69AC1967-6347-49F1-9158-597638D628ADQ36248755-5CB23160-D1A0-4CF4-B3F8-95A9D219DB26Q36291813-37A6C5C0-F03C-4380-8310-4802F2D72F61Q36355288-B8C1E28E-3750-41B7-89FD-06EBF28ADA19Q36360927-1FE9D35F-F3E1-4B07-AC61-8EFC43372D93Q36362075-FCE36406-DC96-496D-8560-1E7043F9805AQ36376363-A8AB681E-5A87-4571-BE81-AFD7768FF828
P2860
Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Segmental flexibility and comp ...... , rabbit and mouse antibodies.
@ast
Segmental flexibility and comp ...... , rabbit and mouse antibodies.
@en
type
label
Segmental flexibility and comp ...... , rabbit and mouse antibodies.
@ast
Segmental flexibility and comp ...... , rabbit and mouse antibodies.
@en
prefLabel
Segmental flexibility and comp ...... , rabbit and mouse antibodies.
@ast
Segmental flexibility and comp ...... , rabbit and mouse antibodies.
@en
P2093
P2860
P1433
P1476
Segmental flexibility and comp ...... , rabbit and mouse antibodies.
@en
P2093
L A Herzenberg
S L Morrison
T G Wensel
P2860
P304
P407
P577
1988-07-01T00:00:00Z